Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES
- Sponsors MaaT Pharma
- 21 Jun 2018 According to a MaaT Pharma media release, the company has received authorization from the French regulatory authorities to start this trial. The company is planning to treat the first patient in the trial in the near future.
- 21 Mar 2018 Dates are not mentioned in EudraCT please update once more information become available.
- 17 Mar 2018 Status changed from planning to recruiting.